To test whether ferroptosis could represent a cancer vulnerability elicited by RB1 deficiency, we carried out in vivo preclinical studies of ferroptosis-inducing therapy in two distinct but complementary tumor model systems. This evidence concerns the gene RB1 and neoplasm.